Article
Psychiatry
Marco Colizzi, Riccardo Bortoletto, Chiara Colli, Enrico Bonomo, Daniele Pagliaro, Elisa Maso, Gianfranco Di Gennaro, Matteo Balestrieri
Summary: PEA, as a naturally occurring molecule, may have neuroprotective and anti-inflammatory properties, improving neurobehavioral functions and combating neurocognitive disorders.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Clinical Neurology
Clara Vila-Castelar, Pierre N. Tariot, Kaycee M. Sink, David Clayton, Jessica B. Langbaum, Ronald G. Thomas, Yinghua Chen, Yi Su, Kewei Chen, Nan Hu, Margarita Giraldo-Chica, Carlos Tobon, Natalia Acosta-Baena, Ernesto Luna, Marisol Londono, Paula Ospina, Victoria Tirado, Claudia Munoz, Eliana Henao, Yamile Bocanegra, Sergio Alvarez, Silvia Rios-Romenets, Valentina Ghisays, Dhruman Goradia, Wendy Lee, Ji Luo, Michael H. Malek-Ahmadi, Hillary D. Protas, Francisco Lopera, Eric M. Reiman, Yakeel T. Quiroz
Summary: This study examined the effect of sex on pathology, neurodegeneration, and memory in cognitively-unimpaired individuals with and without the Presenilin-1 (PSEN1) E280A mutation. The results suggest that females may have greater cognitive resilience to AD pathology and neurodegeneration than males.
ALZHEIMERS & DEMENTIA
(2022)
Article
Clinical Neurology
Christian Schwahn, Stefan Frenzel, Birte Holtfreter, Sandra van der Auwera, Christiane Pink, Robin Buelow, Nele Friedrich, Henry Voelzke, Reiner Biffar, Thomas Kocher, Hans Joergen Grabe
Summary: Through a study of 177 periodontally treated patients and 409 untreated subjects, it was found that periodontal treatment has a positive effect on AD-related brain atrophy, while the effect on brain aging remains uncertain.
ALZHEIMERS & DEMENTIA
(2022)
Article
Neurosciences
Minjae Kim, Dahyun Yi, Min Soo Byun, Hyejin Ahn, Joon Hyung Jung, Nayeong Kong, Yoonyoung Chang, Hyeji Choi, Jungmin Choi, Kyungtae Kim, Gijung Jung, Dong Young Lee
Summary: This study aimed to develop a culturally appropriate cognitive composite that can sensitively identify subtle cognitive decline in Korean older adults with preclinical Alzheimer's disease (AD). Through careful selection of tests for various cognitive functions, a final cognitive composite (CPAD) for Korean older adults was established.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
Chelsea G. Cox, M. M. Ryan, D. L. Gillen, J. D. Grill
Summary: The study found that some participants perceived the need for a study partner as a barrier to enrolling in preclinical Alzheimer's disease trials, while others may have concerns about sharing their biomarker results. Most participants viewed having a study partner as an advantage for trial enrollment, even expressing a desire to have their partner present during biomarker disclosure.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2021)
Article
Clinical Neurology
Lorenzo Barba, Samir Abu Rumeileh, Giovanni Bellomo, Federico Paolini Paoletti, Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Federico Massa, Lorenzo Gaetani, Lucilla Parnetti, Markus Otto
Summary: This study found that beta-syn levels in cerebrospinal fluid (CSF) increase in patients with Alzheimer's disease (AD) in the mild cognitive impairment (MCI) and dementia stages. In contrast, the behavior of other synaptic biomarkers, such as alpha-syn, and biomarkers of neuro-axonal damage, such as NfL and t-tau, is different. CSF beta-syn has the best diagnostic performance for distinguishing pre-AD patients from non-AD patients.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
News Item
Multidisciplinary Sciences
McKenzie Prillaman
Summary: Researchers are cautiously optimistic about the positive results of lecanemab announced by companies.
Article
Medicine, Research & Experimental
Juan Lantero-Rodriguez, Anniina Snellman, Andrea L. Benedet, Marta Mila-Aloma, Elena Camporesi, Laia Montoliu-Gaya, Nicholas J. Ashton, Agathe Vrillon, Thomas K. Karikari, Juan Domingo Gispert, Gemma Salvado, Mahnaz Shekari, Christina E. Toomey, Tammaryn L. Lashley, Henrik Zetterberg, Marc Suarez-Calvet, Gunnar Brinkmalm, Pedro Rosa Neto, Kaj Blennow
Summary: Alzheimer's disease has a long preclinical phase and requires biomarkers for early pathological changes. P-tau235 may be a key feature and staging biomarker. A new CSF p-tau235 assay shows promise in clinical research.
EMBO MOLECULAR MEDICINE
(2021)
Article
Psychiatry
Hao Hu, Lan Tan, Yan-Lin Bi, Wei Xu, Lin Tan, Xue-Ning Shen, Xiao-He Hou, Ya-Hui Ma, Qiang Dong, Jin-Tai Yu
Summary: The study found that hypomethylation of the BIN1 promoter in peripheral blood is associated with early cognitive decline in late-onset Alzheimer's disease (LOAD). Additionally, changes in methylation levels are correlated with alterations in AD-related biomarkers in cerebrospinal fluid, particularly in participants with significant AD biological characteristics and subjective cognitive decline (SCD).
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Clinical Neurology
Philip S. Insel, Christina B. Young, Paul S. Aisen, Keith A. Johnson, Reisa A. Sperling, Elizabeth C. Mormino, Michael C. Donohue
Summary: The rates of tau accumulation in cognitively unimpaired older adults are subtle and vary in magnitude and spatial patterns. The degree of regional accumulation also likely depends on the amyloid-beta-dependent accumulation. Therefore, it is important to evaluate the pattern and consistency of tau accumulation across multiple cohorts and its relationship with amyloid burden to design optimal tau endpoints for clinical trials.
Article
Clinical Neurology
Yara J. Yakoub, Nicholas Ashton, Cherie Strikwerda-Brown, Laia K. Montoliu-Gaya, Thomas Karikari, Przemyslaw R. Kac, Fernando Gonzalez-Ortiz, Jonathan Gallego-Rudolf, Pierre-Francois Meyer, Frederic St-Onge, Michael Schoell, Jean-Paul Soucy, John C. S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve
Summary: Plasma biomarkers can indicate changes in individuals with preclinical AD, as seen in the decreased A beta(42/40) ratio and increased NfL and GFAP values over a 4-year follow-up. Carriers of the APOE epsilon 4 allele showed a faster increase in plasma pTau181, while older individuals had a faster increase in plasma NfL and females showed a faster increase in plasma GFAP values.
ALZHEIMERS & DEMENTIA
(2023)
Review
Pharmacology & Pharmacy
Mohammad Rafi Khezri, Keyvan Yousefi, Negin Mahboubi, Darya Hodaei, Morteza Ghasemnejad-Berenji
Summary: Alzheimer's disease (AD) is a common neurodegenerative disorder worldwide, and its association with diseases like diabetes has been well-studied. Metformin, a medication commonly used for type 2 diabetes, has shown potential disease-modifying effects on various aspects of AD pathophysiology.
BIOCHEMICAL PHARMACOLOGY
(2022)
Review
Cell Biology
Er-Jin Wang, Ming-Yue Wu, Jia-Hong Lu
Summary: This review systematically reviews and meta-analyzes published pre-clinical research on the effects of ferulic acid in treating Alzheimer's disease. The results show that ferulic acid treatment can improve rodents' spatial memory ability and reduce A beta deposition in various model animals.
Article
Clinical Neurology
Fred B. Ketchum, Nathaniel A. Chin, Joshua Grill, Carey E. Gleason, Claire Erickson, Lindsay R. Clark, Jane S. Paulsen, Amy J. H. Kind
Summary: This article discusses the safety and psychological effects of AD biomarker testing, as well as the counseling and risk management before and after testing. It proposes a conceptual model to guide the different phases of testing.
ALZHEIMERS & DEMENTIA
(2022)
Article
Clinical Neurology
Jason M. Doherty, Samantha A. Murphy, Sayeh Bayat, Julie K. Wisch, Ann M. Johnson, Alexis Walker, Suzanne E. Schindler, Beau M. Ances, John C. Morris, Ganesh M. Babulal
Summary: In this study, we investigated the relationship between preclinical Alzheimer's disease biomarkers and adverse driving behaviors using naturalistic driving data. It was found that cerebrospinal fluid biomarkers predicted the incidence of adverse driving behavior over time, and abnormal amyloid beta ratio was associated with an increase in such behaviors.
ALZHEIMERS & DEMENTIA
(2023)
